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Honokiol is a poly-phenolic compound that exerts neuroprotective properties through a
variety of mechanisms. It has therapeutic potential in anxiety, pain, cerebrovascular injury,
epilepsy, and cognitive disorders including Alzheimer’s disease. It has been traditionally
used in medical practices throughout much of Southeast Asia, but has now become more
widely studied due to its pleiotropic effects. Most current research regarding this com-
pound has focused on its chemotherapeutic properties. However, it has the potential to
be an effective neuroprotective agent as well. This review summarizes what is currently
known regarding the mechanisms involved in the neuroprotective and anesthetic effects
of this compound and identifies potential areas for further research.
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INTRODUCTION
Honokiol is a naturally occurring, pleiotropic lignan that can be
extracted from Magnolia grandiflora, a species of magnolia com-
mon to Japan, and is used in traditional medicines throughout
much of Asia. This compound has also been found in several
other Magnolia species, including Magnolia dealbata, an endan-
gered endemic species found in Mexico (1–3). Like the flavorful
tannins present in wine, honokiol, and its structural analog, mag-
nolol, are poly-phenolic compounds; both with a fragrant and
spicy odor. Although aromaticity is not uncommon among anes-
thetics (lidocaine, propofol, etomidate, etc.) only propofol has a
phenol ring like honokiol and magnolol. The structural homol-
ogy likely explains some of the similar pharmacologic action
(Table 1) (4, 5).
Honokiol is known for its anxiolytic (6–9), analgesic (10), anti-
depressant (11, 12), antithrombotic (13), antimicrobial (14–16),
antispasmodic (17), anti-tumorigenic, and neuroprotective prop-
erties (18–27). While its pharmacokinetics have been studied in
rodent models, these parameters have yet to be defined in humans
(28). In rats, i.v. injection of honokiol 5–10 mg/kg has a plasma
t 1/2 of approximately 40–60 min (29). Meanwhile, intraperitoneal
injection in mice of 250 mg/kg has yielded a t 1/2 of 4–6 h, with
a t max of about 20–30 min (30). Due to its gaining popularity in
western medical research, honokiol has been modified and syn-
thesized for delivery through various modalities, including oral,
intravenous, liposomal, and transdermal preparations (31–33).
Honokiol may have some benefits in the peri-operative period, not
only for its anxiolytic, analgesic, and antimicrobial effects, but also
specifically for its potential role in neurologic and oncologic pro-
cedures. This review focuses primarily on honokiol’s effects in the
central and peripheral nervous systems and its role in neuroprotec-
tion as related to its anxiolytic, analgesic, and anti-inflammatory
actions.
NEUROPROTECTION
It is known that honokiol can readily cross the blood brain bar-
rier in order to exert its anti-tumorigenic effects in the central
nervous system (34, 35). It might be assumed that because of
its accessibility to neuronal tissue, honokiol has direct benefi-
cial effects on cellular health as opposed to neuroprotection via
promotion of alternate endogenous pathways. However, honokiol
appears to exert its neuroprotective effects through a wide range
of mechanisms (Figure 1).
In pre-clinical investigations, honokiol has been found to miti-
gate the effects of stroke and seizure and improve performance on
learning and memory tests in behavioral models. Liou et al. admin-
istered honokiol intravenously either pre-ischemia [i.e., 15 min
before unilateral middle cerebral artery (MCA) occlusion] or
post-ischemia (i.e., administered upon removal of both common
carotid arteries clips). Intravenous infusion of honokiol 10−4 and
10−3 mg/kg in both groups significantly reduced the total volume
of infarction without creating significant hemodynamic changes
(25). A subsequent study involved administration of intravenous
honokiol 15 min before or 60 min after MCA occlusion leading to
a dose-dependent reduction of the infarct volume by 20–70% (26).
Similarly, in a rodent model of seizure disorder, the behavioral and
neurotoxic effects of injection of NMDA into the cerebral ventric-
ular system following acute seizure were measured by impairments
in locomotion, climbing, and rotarod performance. These neuro-
toxic impairments were ameliorated by treatment with honokiol
alone or combined with the NMDA antagonist, memantine. Tea
polyphenol or memantine alone only partially ameliorated these
behavioral impairments, indicating a comparatively augmented
neuroprotective role for honokiol in seizure disorder (36).
Honokiol’s neuroprotective effects may be related to the pro-
motion of healthy connections among nerve cells, as honokiol
and its synthetic analogs have potent neurotrophic activity in vitro
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Table 1 | Structure and properties of phenolic compounds with neuroprotective bio-activity.
Propofol Honokiol Magnolol
Chemical structure
Solubility Lipid Lipid Lipid
Receptors with known activity GABAA, Na+ channel GABAA, NFkB, NMDA GABAA, NFkB, NMDA
Applications Sedative-hypnotic, anti-emetic,
neuroprotectant
Anxiolytic, analgesic, anti-inflammatory,
anti-tumor, neuroprotectant
Antibacterial, antioxidant,
anti-inflammatory, neuroprotectant
FIGURE 1 | Honokiol promotes neuroprotection through various
mechanisms. Honokiol results in neuronal protection through preservation
of Na+/K+ ATPase, phosphorylation of pro-survival factors, preservation of
mitochondria, and modulation of GABAA. Honokiol further promotes
neuronal health through prevention of glucose, ROS, and inflammatory
mediated damage.
(37–39). Several putative pathways for neuroprotection have been
investigated including inhibition of the immune system and
oxidative stress pathways. For example, Chen et al. suggest that
honokiol preserves Na+/K+-ATPase activity and enzymatic mito-
chondrial function in mice (19). Meanwhile, Harada et al. suggest
that protection post-ischemia by honokiol can be attributed to
suppressing the development of post-ischemic glucose intoler-
ance and subsequent neuronal damage (21). In rats, Liou et al.
found that honokiol also ameliorates cerebral infarction from
ischemia-reperfusion injury via inhibition of neutrophil infil-
tration and reactive oxygen species (ROS) production as mea-
sured by luminol amplified chemiluminescence in neutrophils
(25, 26). Another group examined the effects of honokiol fol-
lowing cerebral-ischemia-reperfusion injury, and determined that
disruption of the postsynaptic density protein PSD95 and calcium-
dependent neuronal nitric oxide synthase (nNOS) interface is the
primary mechanism of honokiol’s protective effect, since PSD95-
nNOS coupling to the NMDA receptor allows neurotoxic calcium
influx through the NMDA receptor channels and could thereby
result in neurotoxicity (23). Recently, inducers of the inflamma-
tory cascade have been implicated in honokiol’s neuroprotective
properties as well. Specifically, honokiol inhibits the inflammatory
reaction during cerebral-ischemia-reperfusion by suppressing glial
NFκB activation and cytokine production (27). Thus, it seems that
honokiol may exert its neuroprotective effects during and after
cerebral ischemic injury through a variety of mechanisms.
In addition to its potential role in stroke therapy, honokiol
may have a role in seizure prevention as well. Honokiol’s central
depressant activity was first described in the 1980s (40). Sub-
sequently, both honokiol and magnolol have been evaluated as
potential therapies for epilepsy and related disorders. Using rat
cerebellar granule cells, Lin et al. observed the ability of honokiol
to inhibit repetitive firing by blocking glutamate, NMDA and K+
evoked cationic influx. Other studies using intraperitoneal injec-
tions of honokiol or magnolol (1 and 5 mg/kg) were determined
to increase seizure threshold with intravenous infusion of NMDA
(10 mg/ml). Although both compounds significantly increased
seizure thresholds, honokiol appeared to be more potent (41).
The potential for honokiol to promote cognitive health has
been further investigated using neuronal cultures and animal
models designed to test learning and memory. Oral honokiol
(1 mg/kg) and magnolol (10 mg/kg) prevented the age-related
memory and learning deficits found in senescence-accelerated
mice by preserving cholinergic neurons and enhancing phos-
phorylation and activity of Akt, a member of the pro-survival
pathway (42). Hoi et al. examined nine isolated compounds
from Chinese herbs (honokiol, magnolol, vitamin E, salidro-
side, bilobalide, baicolin, gastrodin, α-asarone, and β-asarone)
for potential anti-Alzheimer’s activity in neuronal cultures, but
only honokiol and magnolol significantly decreased β-amyloid
(Aβ)-induced neuronal death (22). Decreased ROS production,
suppressed intracellular calcium elevation, and inhibition of
caspase-3 activity may all contribute to honokiol’s neuropro-
tective effects in Aβ toxicity. The potential for honokiol to be
therapeutic for neurodegenerative disease is supported by evi-
dence that a honokiol-containing extract of Magnolia officinalis
(10 mg/kg in 0.05% ethanol) prevents lipopolysaccharide (LPS)-
induced memory deficiency via its antineuroinflammatory and
antiamyloidogenic effects (43).
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ANXIOLYSIS AND SLEEP
Honokiol’s central depressant effects may contribute not only
to its anticonvulsant activity but also to its anxiolytic activity
at low doses. This can be partially attributed to its interaction
with the GABAA receptor, a known target for benzodiazepines
and other anxiolytics. When Kuribara et al. examined the effects
of orally administered honokiol in an animal behavior model, they
showed that a single oral dose of honokiol increased exploratory
behavior while decreasing anxiety-related behavior. This effect
was observed with repeated doses as low as 0.2 mg/kg. Honokiol
achieved this with less motor or cognitive side effects than oral
diazepam. This effect of honokiol was inhibited by administra-
tion of subcutaneous flumazenil, bicuculline (a GABAA receptor
antagonist), CCK-4, and caffeine. Flumazenil and bicuculline like-
wise disrupted the anxiolytic effect of diazepam, but CCK-4 and
caffeine co-administration with diazepam had quite different out-
comes. The combined administration of diazepam with caffeine
enhanced diazepam’s anxiolytic effect, and diazepam completely
reversed the effect of CCK-4. The authors concluded that honokiol
produces anxiolysis with a better side effect profile than diazepam,
and based on their results with caffeine, possibly through alterna-
tive pathways (9). Certain ortho (C2) and para (C4) substitutions
increase the GABA-potentiating activity of phenols, and honokiol
and magnolol have shown specific selectivity for different GABAA
receptor subtypes (44, 45). Taferner et al. examined modulation
of GABAA receptors by honokiol and derivatives as well, looking
at subtype selectivity and structure-activity and finding a poten-
tial role of the acetamido group in subunit-dependent receptor
modulation (46).
Glutamic acid decarboxylase (GAD) is an enzyme involved
in GABA synthesis, and the activity of hippocampal GAD was
significantly increased in honokiol-treated mice, suggesting that
honokiol may alter the brain’s synthesis of GABA (47). Because
GABAA receptors have subunit heterogeneity that influences their
function, Alexeev et al. explored the activity of magnolol and hon-
okiol on neuronal and recombinant GABAA receptors. Both com-
pounds enhanced GABA-ergic neurotransmission in hippocampal
dentate granule neurons. All recombinant receptors were sensi-
tive to modulation, regardless of the subunit subtype, however,
both compounds showed higher efficacy at receptors containing
the δ subunit (900–1100% response with a tertiary δ subunit vs.
300–500% response with α, β, and γ subunits only) (48).
A recent study sought to explore the effect of honokiol on
sleep. Honokiol (10 and 20 mg/kg) was found to significantly
shorten sleep latency and to increase the amount of non-rapid
eye movement sleep, though it had no effect on either the amount
of rapid eye movement sleep or EEG power density. This group
also found that honokiol excited sleep-promoting neurons in the
ventrolateral preoptic areas (49). The sleep-promoting and anx-
iolytic effects of honokiol suggest a potential additional role for
this neolignan in the anesthetic arena.
PAIN AND INFLAMMATION
Because of honokiol’s immunomodulatory effects, it is reason-
able to assume that honokiol could be effective in inflammatory
pain states. Formalin-induced paw licking is a common model
for chronic inflammatory pain. Formalin produces a biphasic
pain response following intraplantar injection, resulting in an
acute pain phase that lasts approximately 5 min immediately
following formalin injection, and an inflammatory pain phase
that is observed 30–45 min following formalin injection, as evi-
denced by increased paw-licking behavior (50). Lin et al. showed
that honokiol and magnolol reduced the inflammatory phase of
formalin-induced paw-licking in mice and decreased formalin-
induced c-Fos protein expression in superficial (I-II) laminae of
the L4-L5 lumbar dorsal horn (51). This same group later studied
the effects of honokiol and magnolol on paw-licking and ther-
mal hyperalgesia induced by glutamate receptor agonists injected
into the hind paws of mice. They found that honokiol and mag-
nolol were similar in their ability to block the pain responses
induced by glutamate, substance P, and PGE2, but honokiol was
more selective than magnolol for inhibition of NMDA-induced
licking behavioral and thermal hyperalgesia. For example, the
same dose of either honokiol or magnolol (10 mg/kg) reduced
glutamate-induced licking time and increased the latency to paw
withdrawal from hot water in a test of thermal hyperalgesia. Addi-
tionally, intraplantar injection of honokiol or magnolol reduced
total licking time and thermal hyperalgesia induction by NMDA
in a dose-dependent fashion. Although in substance P – induced
thermal hyperalgesia, magnolol was found to be slightly more
effective than honokiol at lower doses, for PGE2-induced nocicep-
tion and hyperalgesia, honokiol significantly decreased behavioral
responses to pain at lower doses than magnolol. At physiologically
relevant dosages, both compounds were able to significantly atten-
uate PGE2-induced thermal hyperalgesia up to 120 min following
pain induction (10).
In an effort to probe deeper into honokiol’s anti-inflammatory
effects, Chao et al. used LPS to induce inflammation and found
that honokiol decreased tumor necrosis factor-alpha secretion
in mouse macrophages following LPS. Additionally, honokiol
inhibited nitric oxide expression in macrophages, protein kinase
C-α membrane translocation, and NF-κB activation (52). This
anti-inflammatory action can be translated to human monocyte-
derived dendritic cells (53). These studies are supported by work
from Murakami et al. who found similar inhibitory effects of
honokiol on NF-κB activation and COX-2 expression (54).
Thus, it seems that honokiol’s analgesic effects are multifactor-
ial, likely involving the inflammatory cascade, the NMDA receptor,
and inhibition of well-known inflammatory pain mediators (e.g.,
glutamate and substance P). Honokiol would likely be a useful
adjunct for treatment of inflammatory pain states, once its side
effect profile has been adequately elucidated.
FUTURE DIRECTIONS AND POTENTIAL RISKS
Honokiol appears to have several potential roles as a therapeutic
for anesthesiologists, neurologists, and pain physicians. Although
it has been used in traditional medicines for thousands of years, a
thorough understanding of its bio-activity will aid in applying
this compound or its derivatives to human pathologic condi-
tions. It appears to specifically target tumorous cells in the CNS
while preserving and protecting healthy neurons and preventing
deleterious results from ischemia, seizure, amyloidosis, anxiety,
depression, and pain (8, 9, 11, 12, 22, 28, 35, 55, 56). It is possible
that many of honokiol’s downstream anti-inflammatory effects
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could result from modulation at a single upstream site that is
yet to be elucidated. Its lipid solubility likely further contributes
to its ability to act at multiple sites by allowing the compound
to cross lipid bi-layers and exert its action intracellularly and
beyond the blood brain barrier. Perhaps the reason for honokiol’s
pleiotropic effects can be attributed partially to its chemical struc-
ture, which allows it certain similarities to propofol. Polyphenols,
like phenols, are small compounds capable of interacting with sev-
eral membrane proteins through hydrogen bonding, hydrophobic
interactions, or the sharing of pi electrons due to aromaticity.
Propofol, like honokiol, has a role not only as an anesthetic,
but more recently as a neuroprotectant, anti-inflammatory, and
anti-tumorigenic agent as well (57–59). It is likely that as fur-
ther research is performed using propofol, honokiol, and other
compounds with similar structure, more commonalities will be
discovered among them, which will help to further define their
mechanisms of action.
Honokiol is not entirely without risks, although its limited
empirical application to humans at therapeutic doses has lim-
ited the evaluation of its side effect profile thus far. There are
potential risks that can be expected, including increased bleed-
ing and potential neurotoxicity at high doses. Honokiol has been
found to be a potent inhibitor of arterial thrombosis, so it may be
advisable to avoid honokiol in coagulopathic patients or in those
where bleeding or hemorrhage may be of concern (13). These
may include patients with hemorrhagic stroke, patients with hem-
orrhagic changes following ischemic stroke, patients on coumadin
or therapeutic lovenox, and patients with clotting disorders such as
hemophilia or von Willebrand’s deficiency. And, while honokiol
has been found to have neuroprotective effects at low doses, it
has also been found to increase neuronal death in vitro at higher
doses (100µM applied directly to fetal cortical neurons) (38).
This suggests a need to further study its pharmacokinetic and
pharmacodynamic parameters in humans before unintentionally
administering a potentially toxic dose of this compound. Although
the pharmacodynamics and pharmacokinetics of honokiol have
now been well-studied in rats, further studies need to be per-
formed in humans before it can be widely administered (29, 60,
61). With modifications of its structure and methods of delivery
helping to improve its functionality at multiple targets, includ-
ing the GABA receptor and its subunits, serotonergic receptors,
and members of the inflammatory cascade, honokiol stands as a
promising new therapeutic agent for a variety of conditions.
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